The Treatment Landscape for Relapsed/Refractory PTCL in Europe

Zinzani outlines the limited options available to European patients with relapsed or refractory peripheral T-cell lymphoma, emphasizing how few effective therapies exist once frontline treatment fails. He describes a reliance on single-agent chemotherapies such as bendamustine and gemcitabine, sometimes combined as part of regimens used more broadly in lymphoma management. Zinzani stresses that the outcomes with these approaches remain consistently poor regardless of histologic subtype, with overall response rates that rarely exceed roughly 30%, complete metabolic responses in only a small minority of patients, and progression-free survival measured in just a few months. He frames this as a genuinely difficult and longstanding clinical situation, one that leaves clinicians with little to offer patients whose disease has returned. The segment establishes the European baseline against which newer agents such as duvelisib must be judged, underscoring the substantial unmet need that motivates ongoing trial efforts across the continent.